VTGN

Vistagen Therapeutics, Inc. Common Stock

0.59

USD

VTGN Earnings Reports

Positive Surprise Ratio

VTGN beat 20 of 38 last estimates.

53%

Next Report

Date of Next Report

Jun 15, 2026

Estimate for Q4 26 (Revenue/ EPS)

$273.02K

-$0.34

Implied change from Q3 26 (Revenue/ EPS)

-9.89%

-24.44%

Implied change from Q4 25 (Revenue/ EPS)

+1720.15%

-20.93%

Vistagen Therapeutics, Inc. Common Stock earnings per share and revenue

On Feb 12, 2026, VTGN reported earnings of -0.45 USD per share (EPS) for Q3 26, beating the estimate of -0.49 USD, resulting in a 9.22% surprise. Revenue reached 303.00 thousand, compared to an expected 373.32 thousand, with a -18.84% difference. The market reacted with a -7.23% price change (close before vs. close after earnings).

Looking ahead to Q4 26, 7 analysts forecast an EPS of -0.34 USD, with revenue projected to reach 273.02 thousand USD, implying an decrease of -24.44% EPS, and decrease of -9.89% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Femasys Inc. Common Stock

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.01

Surprise

+88.80%

Tevogen Bio Holdings Inc. Common Stock

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$2.04

Actual

-$1.45

Surprise

+28.92%

Soligenix, Inc. Common Stock

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$0.57

Actual

-$0.28

Surprise

+50.98%

Kairos Pharma, Ltd.

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$0.05

Actual

-$0.07

Surprise

-28.68%

BioAtla, Inc. Common Stock

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$0.24

Actual

-$0.16

Surprise

+34.64%

CNS Pharmaceuticals, Inc. Common Stock

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$5.19

Actual

-$10.15

Surprise

-95.50%

HCW Biologics Inc. Common Stock

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$0.85

Actual

-$3.19

Surprise

-272.32%

Pharvaris N.V. Ordinary Shares

Report Date

Apr 02, 2026 For Q4 25

Estimate

-$0.63

Actual

-$0.72

Surprise

-13.69%

Nanobiotix S.A. - ADR

Report Date

Mar 31, 2026 For Q4 25

Estimate

$0.55

Actual

-$0.39

Surprise

-170.16%

Palvella Therapeutics, Inc. Common Stock

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$0.92

Actual

-$1.07

Surprise

-15.20%

FAQ

What were Vistagen Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, Vistagen Therapeutics, Inc. Common Stock reported EPS of -$0.45, beating estimates by 9.22%, and revenue of $303.00K, -18.84% below expectations.

How did the market react to Vistagen Therapeutics, Inc. Common Stock's Q3 2026 earnings?

The stock price moved down -7.23%, changed from $0.55 before the earnings release to $0.51 the day after.

When is Vistagen Therapeutics, Inc. Common Stock expected to report next?

The next earning report is scheduled for Jun 15, 2026.

What are the forecasts for Vistagen Therapeutics, Inc. Common Stock's next earnings report?

Based on 7 analysts, Vistagen Therapeutics, Inc. Common Stock is expected to report EPS of -$0.34 and revenue of $273.02K for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.